Revance Therapeutics Inc (NAS:RVNC)
$ 2.89 0.09 (3.21%) Market Cap: 301.86 Mil Enterprise Value: 490.12 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 59/100

Q4 2020 Revance Therapeutics Inc Earnings Call Transcript

Feb 22, 2021 / 09:30PM GMT
Release Date Price: $26.96 (-3.71%)
Operator

Welcome to the Revance Therapeutics Fourth quarter and Full Year 2020 Financial Results and Corporate Update Conference Call. (Operator Instructions) As a reminder, this call is being recorded today, February 22, 2021.

I would now like to turn the conference call over to Jessica Serra, Head of Investor Relations and ESG for Revance. Please go ahead.

Jessica Serra
Revance Therapeutics, Inc. - Head of IR & ESG

Thank you, Faith. Joining us on the call today from Revance is President and Chief Executive Officer, Mark Foley; Chief Financial Officer, Toby Schilke; Chief Operating Officer and President of R&D and Product Operations, Dr. Abhay Joshi; Chief Commercial Officer, Aesthetics and Therapeutics, Dustin Sjuts; President of Innovation and Technology, Aubrey Rankin; and Senior Vice President, Clinical Development, Dr. Roman Rubio.

During this call, management will make forward-looking statements, including statements related to Revance's 2021 guidance, the clinical development of our product candidates, business strategy and planned

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot